Covid 19 Research using Clinical Trials (Home Page)
CYNK-001Wiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug505 | Hydroxychloroquine Wiki | 0.11 |
| drug850 | Placebo Wiki | 0.09 |
Correlated MeSH Terms (14)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D030341 | Nidovirales Infections NIH | 1.00 |
| D007154 | Immune System Diseases NIH | 0.71 |
| D003333 | Coronaviridae Infections NIH | 0.58 |
| D012327 | RNA Virus Infections NIH | 0.50 |
| D008171 | Lung Diseases, NIH | 0.41 |
| D012140 | Respiratory Tract Diseases NIH | 0.32 |
| D012141 | Respiratory Tract Infections NIH | 0.23 |
| D011024 | Pneumonia, Viral NIH | 0.14 |
| D014777 | Virus Diseases NIH | 0.14 |
| D003141 | Communicable Diseases NIH | 0.11 |
| D011014 | Pneumonia NIH | 0.07 |
| D007239 | Infection NIH | 0.07 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
| D018352 | Coronavirus Infections NIH | 0.05 |
Correlated HPO Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002088 | Abnormal lung morphology HPO | 0.41 |
| HP:0011947 | Respiratory tract infection HPO | 0.23 |
| HP:0002090 | Pneumonia HPO | 0.07 |
There is one clinical trial.
Clinical Trials
1 A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in hospitalized patients with moderate COVID-19 disease.
NCT04365101 Coronavirus Coronavirus Infection Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia Pneumonia, Viral Lung Diseases Respiratory Tract Disease Respiratory Tract Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Virus Disease Immunologic Disease ARDS Immunologic Factors Physiological Effects of Drugs Antiviral Agents Anti-infective Agents Analgesics Antimetabolites, Antineoplastic Biological: CYNK-001 MeSH:Infection Communicable Diseases Respiratory Tract Infections Coronavirus Infections Severe Acute Respiratory Syndrome RNA Virus Infections Pneumonia, Viral Coronaviridae Infections Nidovirales Infections Pneumonia Lung Diseases Virus Diseases Respiratory Tract Diseases Immune System Diseases
HPO:Abnormal lung morphology Pneumonia Respiratory tract infection
Primary Outcomes
Description: Number and severity of adverse events
Measure: Phase 1: Frequency and Severity of Adverse Events (AE) Time: Up to 12 months
Description: Time from the date of randomization to the clearance of SARS-CoV-2 by rRT-PCR
Measure: Time to Clearance of SARS-CoV-2 Time: Up to 12 months
Description: Time from the date of randomization to the first date of clinical improvement of cough.
Measure: Time to Clinical Improvement of cough Time: Up to 28 days
Description: Time from the date of randomization to the first date of clinical improvement of radiological evaluation of disease related chest x-ray
Measure: Time to Clinical Improvement in radiological evaluation of disease related chest x-ray Time: Up to 28 days
Description: Proportion of subjects who achieve pulmonary clearance
Measure: Rate of Pulmonary Clearance Time: Up to 28 days
Description: Proportion of subjects who achieved clinical improvement of radiological evaluation of disease related chest x-ray
Measure: Rate of Clinical Improvement of radiological evaluation of disease related chest x-ray Time: Up to 28 days
Secondary Outcomes
Description: Number and severity of adverse events
Measure: Phase 2: Frequency and Severity of Adverse Events (AE) Time: up to 12 months
Description: Time to medical discharge as an assessment of overall clinical benefit
Measure: Overall Clinical Benefit by time to medical discharge Time: up to 12 months
Description: Hospital utilization will be measured as an assessment of overall clinical benefit
Measure: Overall Clinical Benefit by hospital utilization Time: up to 12 months
Description: Mortality rate will be measured as an assessment of overall clinical benefit
Measure: Overall Clinical Benefit by measuring mortality rate Time: up to 12 months
Description: Assess the impact of CYNK-001 on changes in sequential organ failure assessment (SOFA) score.
Measure: Impact of CYNK-001 on sequential organ failure assessment (SOFA) score Time: Up to 28 days
Description: Time from randomization to the date of disappearance of virus from lower respiratory tract infection (LRTI) specimen where it has previously been found (induced sputum, endotracheal aspirate).
Measure: Time to Pulmonary Clearance Time: Up to 28 days
Description: Proportion of subjects who achieved clinical improvement of cough
Measure: Rate of Clinical Improvement of cough Time: Up to 28 days
Description: Proportion of subjects who achieved clinical improvement of fever
Measure: Rate of Clinical Improvement of fever Time: Up to 28 days
Description: Time from the date of randomization to the first date of clinical improvement of fever
Measure: Time to Clinical Improvement of fever Time: Up to 28 days
Description: Proportion of subjects with "negative" measurement of COVID-19 by rRT-PCR
Measure: Rate of Clearance of SARS-CoV-2 Time: Up to 12 months
Related HPO nodes (Using clinical trials)
HP:0002088: Abnormal lung morphology
Genes 1217
GATA6 COL13A1 DNAI1 EPG5 CSPP1 ABCA12 IL2RG PORCN TGFB2 COL1A1 SOX11 IL17RC PEX1 SLC12A6 CSF2RA TCF4 NAA10 TCTN3 INSR GAS8 TTC37 SERPINF2 BRAF DOCK6 RBPJ NOD2 CLEC7A PSAP VPS33A CTRC ATM TGFB1 BCL10 BAP1 CCDC39 STN1 CD8A OCRL DNAH11 CHD7 TINF2 FOXP3 ERCC6 RANBP2 CR2 C11ORF95 PIEZO2 LACC1 DSE SETBP1 ZMPSTE24 CD3D MALT1 ADGRG6 PLP1 TINF2 SPAG1 TAP2 AGA ERAP1 IL7R CFI RUNX2 LAT DNAAF4 MAP3K8 IL17RA CHST14 ADA DNASE1L3 DNAI2 DNAH5 FOXP1 TBX1 PIEZO1 DNAH1 NKX2-5 ELP1 DCLRE1C MTHFD1 LOX TSC2 FGFR3 SOS1 IRF8 CHAMP1 EFEMP2 WDR35 CCDC39 PIK3CD HABP2 SDCCAG8 PRKN CD81 TNFSF12 ARMC4 NCF2 SMN1 RMRP TBC1D23 CHRNA1 DSG1 GDF1 NKX2-1 POLR3H SMPD1 WDR60 ATP5F1A UBE2A GLE1 COL2A1 FLCN EIF2AK4 ACTA1 RPL10 IPW MYO5A MEFV NHP2 RYR1 PIGN DGCR2 NFKB1 CCBE1 DNAH11 FCGR2B SLC26A2 FBLN5 RAG1 SOX4 PTEN PTPN11 ARMC4 DCLRE1C PSAT1 STAT3 SERPINF2 STAT3 STAT3 PARN SEC24C TSC1 RAB3GAP2 GLI3 C1R GBA ALB ADAMTS3 PIGN UMPS HLA-DRB1 LEPR SLCO2A1 BLM ACVRL1 THOC2 MMP21 CARD11 CFTR USP9X DNMT3B COL6A1 TNFSF11 FAM20C RYR1 PPP2R1B PEPD HLA-DPA1 MUSK LMNA GATA6 FBLN5 LMOD3 DIS3L2 SNORD115-1 SCNN1G GNPTAB COL5A2 KIAA0319L CXCR4 IDUA CCR6 BMP2 SNX10 MED25 CFAP410 BCOR LTBP4 STRA6 TERT EDARADD POLE FOXF1 STAT1 LIPN DRC1 VPS13A NFKB1 STK36 PTPN11 CCDC22 SLC1A4 SULT2B1 PPP1CB TAP1 IFT80 CFAP298 ZBTB24 GATA4 PIK3R1 DNAH5 GLI1 TGFB3 HPS1 DNASE1 WDR19 CEP55 ELN SMPD1 ICOS DCTN4 NUMA1 DKC1 LIG4 SMAD4 FBLN5 ACADVL PRPS1 BCL6 GPC3 AGRN RIPK1 FMO3 SNAP25 CSF2RA MUSK MAGEL2 HGSNAT STAT5B DNAAF5 GBA TTC25 CEP57 RAB27A FGF20 SLC2A10 PMM2 DGCR6 RREB1 ASAH1 CCR6 LFNG SLC35A1 IKBKB PGM3 CCDC40 BICC1 EPHB4 PEPD NSDHL MCM4 COG4 SPINK5 HLA-DRB1 WRN BMP15 KCNJ6 GP1BB GLI3 STING1 GPC3 NABP1 RARB ARHGAP31 MAPK1 ERBB2 B2M POLA1 NBN KRAS CYBC1 CFB STAT3 SP110 MCIDAS PRTN3 EOGT IL2RB MEFV MKKS PIGL ATM TERT HOXD13 ENG CHAT DICER1 DGCR8 PKD1L1 MIF FRAS1 DNAJB13 TERT ZMYND10 MKRN3-AS1 TPM2 CD247 SCNN1A COL3A1 TRAF3IP2 SMPD1 MITF RSPH4A FLI1 COLQ LETM1 NFE2L2 ITCH LPIN2 TBCE VAMP1 TPP2 PIK3CA ZBTB24 ZAP70 CD3G CASP8 NR2F2 H19 OSTM1 COPA MESP2 PKHD1 BNC1 PRKAR1A CTCF RBM10 GLI3 GAA PRKAG2 SLC46A1 CHRM3 MYSM1 DNAI2 SLC29A3 CD3E SPAG1 RELA COL11A2 PML TNFRSF13C RSPH3 SCNN1G SFTPA2 SH3KBP1 CD79B SRP54 SMAD3 WNT4 LMNA CHRNG EPG5 KITLG BACH2 UBB SPIDR MAP3K20 FUZ GREB1L GATA6 TERT GSN KIF11 DHCR24 RFX5 IKBKB LEPR KEAP1 TERC EDNRB CRTAP BCL2 TRPS1 STAT6 SLC35A1 TERC CHRNG INVS COG6 CASP8 CARD11 DNAAF4 RRAS CLIP2 USB1 PYROXD1 FSHR PARN LYST RPL10 WDR60 RFXAP TCF3 PSMC3IP MECP2 IGH CTSC HLA-B TAPBP NOTCH2 GRIP1 GNS DLL3 CEP120 CBL SCNN1B GTF2E2 PARN GPKOW ATP11A TMEM260 TNFRSF13C CEP120 IL21R RFXANK CAV1 TBC1D24 SLC25A24 UBAC2 DHCR7 SGSH GATA4 PNP NFIX USB1 TSC2 TRIP13 IDUA IL23R RFXAP ADA RAG2 DRC1 ADNP NGLY1 WDR60 FLNA POU6F2 BCOR IL2RG NCF1 ROR2 SCN9A SCNN1A TGFB2 NSD2 INTU GTF2H5 SON MYH11 TARS1 LIFR BRAF RET OFD1 ARHGAP31 NOTCH2 SOX18 CTLA4 HELLS ZMYND10 NDN EFEMP2 ALOXE3 NFKBIA PLEC SFTPC TRIP13 MPLKIP RAG1 MYLK IGH USP9X PIGN XIAP NXN TBX5 RASGRP1 NHLRC2 ITGA8 ACTA1 DLL4 ATP6V1E1 TNFRSF11A DSP PCNT CD79B HLA-B GTF2I SMARCD2 EMG1 IL2RA PTPN22 IRF5 BGN ARID1B RSPH9 SAMD9 GUSB BTNL2 TNFRSF13B CYBA DKC1 KIAA0556 ALG12 PTH1R SLC26A2 GPR35 NUP107 HPS4 TBX1 CR2 TRPV4 KRAS PRKCD SLC11A1 EGFR NSMCE3 PLG UNG SGCG RAPSN DNAAF6 RPS15A APOE LYST ACTA2 SNRPN MESP2 TCIRG1 TBC1D24 TIMM8A RAG2 MUC5B IL17F NPAP1 HYDIN SERPINA1 IRF5 FAS CIITA KPTN CACNA1C PEX13 PLCG2 GATA6 COL6A2 DICER1 CTC1 LRRC6 SFTPB FADD TTC7A RNF168 FARSB HYLS1 NPHP3 IFNGR1 GAS8 CFTR SLC34A2 FLCN ALG9 AGTR1 WDR19 TRPV3 IGLL1 CRKL TMEM94 SLC26A2 CLPB FREM2 MYOD1 WDR34 SCNN1B CCN2 PRSS1 TBX6 TSC1 KLHL40 DDR2 CCDC103 MEFV PDGFRA IL2RG NCF4 WT1 RYR1 CACNA1B DYNC2H1 POLR3A DNAAF2 TRAIP CLCA4 JAK3 OFD1 IGHM NECTIN1 IER3IP1 TNFRSF1B DCLRE1C LGI4 BCR NOTCH3 SCARB2 EVC2 IL12A LRRC56 WT1 FASLG RSPO2 PWRN1 HSPG2 RAG2 BUB1 NKX2-1 ESS2 RNU4ATAC IRAK1 ELN MST1 HYDIN SLC2A10 RAF1 TGFBR2 IL12A-AS1 MRPS22 IRAK4 MYH7 DNAH9 NELFA TNFSF12 MYH3 GPC4 SMAD4 TINF2 GRHL3 DOK7 POLA1 ATP6V0A2 TRIM28 LCK DNAI1 SMARCA4 ORC6 CSPP1 MASP2 AKT1 BMPR2 SLC5A7 RSPH3 NAB2 CRELD1 TGFBR2 NIPAL4 LZTR1 G6PC3 CCNO DVL3 FAM13A SFTPC SLC52A3 UFD1 NHP2 EPM2A SCNN1A KIAA0586 MYSM1 RIT1 UNC119 CCDC65 RAG1 ARID2 LRBA FLNB B3GLCT FGFR1 CDCA7 GDF1 FLNA DCLRE1C DHCR24 RAG1 TPM3 SERPINH1 BRCA2 HELLPAR NFKB2 FBN1 NOP10 SFTPA2 FGFR3 JMJD1C RAF1 CD46 RAG2 FAT4 MBTPS2 FCGR2A PHGDH SNORD116-1 WAS SLC18A3 CFTR KDM6A TGFBR1 ICOS SLC25A22 RPGR HLA-DRB1 NCF1 ARSB MKS1 NME8 CITED2 EWSR1 ALMS1 HES7 TSC1 INHBA CR2 IRF1 GRIP1 NEB GFI1 SERPINA1 ARID1A TAF1 NPHP3 HACD1 RNF125 EVC LAMTOR2 SMARCB1 NEK1 CCND1 VHL GLA IDUA CDC42 TERT LAMB2 WDR34 CCDC151 CYP2A6 FOXE1 LEP TECPR2 RSPH4A SPECC1L BIRC3 DYNC2H1 ABL1 PRKDC GLB1 IRF2BP2 TYK2 TCIRG1 STAT4 LRRC56 CFTR TNFRSF13B FRAS1 CORO1A STK11 DNAAF6 IL1RN NRAS PHGDH FCGR3A ASCC1 BTK GMNN ETFA ABCA12 RAC1 COMT NAA10 ACP5 FBN1 RNF168 CD19 GBA LAMA2 NAA10 NFKB2 WAS NFKB2 AK2 MGP SOX10 PTEN GBA RNF113A DNAJB13 FAT4 BLM INPPL1 TNFRSF1A FADD RPGR DNAL1 CFAP298 GATA2 NUP88 BTK REST ZBTB16 FUCA1 DNAAF1 CSF2RB AGGF1 RAG1 ZMPSTE24 GAS2L2 FANCB PTPN22 INPPL1 ALPL MGP HPGD C1QA ELN SLC25A1 DNAAF3 RAG2 TGFB1 FCN3 CAV1 RSPH9 CYBB FANCB BUB3 FLCN GPC6 SMARCE1 ELN COL6A3 DYNC2LI1 AICDA CCN2 ELANE MEFV TERC CCR1 PAX3 CCDC103 ERCC2 KAT6B TRIP11 HLA-DRB1 ITGA8 FASLG KRAS PAX6 CD3E CD19 SMARCC2 WASHC5 TAPT1 SLC18A3 HLA-DRB1 WRAP53 CEP57 MANBA DNAAF5 RFC2 SMAD3 ERCC3 WNT4 CD3D WIPF1 MS4A1 TERC BCL11B CFTR TGFB1 SHROOM4 BLNK CCNQ IL7R MYL2 RHOH CTLA4 RARA RARB RIPK4 CCDC40 EP300 NEK9 IFIH1 SOX18 FLCN SCN10A KIF1A GNPTAB CRELD1 SCNN1B JAK3 IFT140 DOCK8 MBTPS2 ZFPM2 SPINK1 HLA-DRB1 PRKCD ACTA1 NGLY1 MARS1 FOXE3 CCNO FOXC2 RSPH1 KLRC4 PIGT NPM1 SAMD9L MYBPC3 LAMTOR2 ELN TK2 GUSB CARMIL2 ETFDH NRAS LRRC8A ARID1B SELENON LIMK1 FSHR FIP1L1 TBL2 RIT1 ACE RELB SDR9C7 NADK2 PERP SFTPC CHRND AARS2 SLC22A18 ITPR1 TBL1XR1 IL2RG CDC45 ALDH18A1 ICOS STRA6 FCGR2A MARS1 AFF4 KIAA0586 WNT3 IL7R RASA2 RTEL1 HPS6 HERC2 DONSON ERF TP53 IL17RA SCNN1G CLCN7 SCN11A SFTPB WT1 HIRA DPM2 NCF2 TP53 AFF4 EXOSC9 CCBE1 TRIP4 MYH3 NEK8 ELANE NME8 SLC35C1 DNAAF1 DPF2 KMT2D RIPPLY2 CD79A WT1 CCDC114 NBN BLNK TIRAP PCGF2 AGT COL2A1 PLVAP FAS ADAMTS2 DHCR7 DNAAF2 BMPER BUB1B IFT172 RSPH1 CTLA4 HLA-DPB1 CD81 PGM3 NOTCH1 ELN ADA EGFR RLIM NCF4 RB1 STAT1 FLNB CCDC114 CFI RFXANK RSPO2 MSN C4A TNFRSF13B COQ7 MINPP1 PTPN22 CD28 CIITA GALNS NR5A1 DPP9 CC2D2A DNMT3B TTC21B ITGA3 BMPR2 CFAP300 STX1A EHMT1 ITGA7 MFAP5 BTK MYO9A TTC25 SPEF2 TNFRSF13C MKRN3 MAT2A SKIV2L ZNHIT3 SOS2 SFTPA1 CXCR4 PIK3R1 RRAS2 RTEL1 RTEL1 COL3A1 CHST14 TSC1 TRIP11 CD55 FOXJ1 SLC7A7 TBX1 CYTB TLR4 SLC26A2 CYP4F22 COG4 AP3D1 ITCH MCTP2 CD79A GAS2L2 IL10 GLDN NOTCH3 ALOX12B RAG1 ALMS1 RCBTB1 GBA TFRC TSC2 CASP10 NKX2-5 PNP DYNC2LI1 TRIM28 STAT4 ARVCF SH2D1A IL21 ZAP70 PDGFRB RNU4ATAC DNAAF3 P4HTM KLHL41 CCNQ AGA BCOR MYD88 COL5A1 ABCA3 JAG1 TREX1 IGLL1 GLE1 IFT81 LTBP3 ASAH1 NPM1 IKZF1 DICER1 SLC7A7 CYBA HFE CBL RFX5 MS4A1 WNT3 JAGN1 PUF60 ZEB2 NAGLU BTNL2 FAM111B CFAP221 MLXIPL HRAS COL13A1 WDR35 SIK1 TRIP4 PWAR1 ECM1 LMNA TGM1 COL11A2 IRAK4 PRKG1 SELENON FGF20 CD19 IKBKG TGFBR1 DLL3 ELP1 IFT80 BAZ1B CTLA4 REN CHRNG ABCA3 ZNF341 WDR34 EXTL3 KAT6B TERT XIAP MYRF SPP1 CSF2RB CYBB PIK3R1 CCND1 NOP10 MUC5B FBN1 PRSS2 PLOD1 SYT2 KAT6B IGHM PANK2 IFT43 MRAS FAS CFH PTPRC MESP2 FOXP1 FLNA TBCD LBR VPS33A SMN1 IL6 NIPBL LEP NHLRC1 CCDC151 DOCK8 LRRC6 GTF2IRD1 SNAI2 CREBBP AP3B1 ETFB VANGL1 LMNA PRKAR1A A2ML1 CDT1 CCDC65 HP:0002090: Pneumonia
Genes 211
CCDC103 JAK3 IL2RG CD247 DNAI1 DOCK8 CSPP1 RYR1 IL2RG DNAAF2 JAK3 OFD1 PRKCD RSPH4A IGHM CCNO GAS8 DCLRE1C ZBTB24 NOTCH3 ZAP70 OSTM1 TK2 LRRC56 TGFB1 NKX2-1 DNAH11 CHD7 FOXP3 RANBP2 DNAI2 CR2 RNU4ATAC SETBP1 NADK2 SPAG1 COL11A2 TNFRSF13C SFTPC HYDIN DNAH9 IL2RG SRP54 TNFSF12 ICOS FCGR2A ADA DNAH5 GRHL3 UBB AFF4 KIAA0586 IL7R TERT DNAH1 DNAI1 ORC6 MASP2 DCLRE1C RSPH3 MTHFD1 AFF4 IRF8 ELANE CCDC39 NME8 CASP8 CARD11 DNAAF4 SLC35C1 EPM2A CD81 KMT2D TNFSF12 UNC119 LRBA NCF2 USB1 CCDC114 NBN DCLRE1C RMRP NFKB2 SFTPA2 RSPH1 RAG2 ADA EGFR CCDC114 WAS TNFRSF13C KDM6A IL21R TNFRSF13B TBC1D24 ICOS SLC25A24 NFKB1 PNP NFIX RAG1 ARMC4 ADA STAT3 DNMT3B RAG2 CFAP300 BTK GFI1 TAF1 SPEF2 RNF125 IL2RG NCF1 TNFRSF13C CXCR4 CARD11 CD55 OFD1 CCDC151 FOXJ1 ZMYND10 PEPD GNPTAB RAG1 PIGN ALMS1 MED25 CFAP410 BTK RAC1 ACP5 ACTA1 CD19 GBA TNFRSF11A CD79B DRC1 SMARCD2 NFKB2 STK36 ZAP70 RNU4ATAC DNAAF3 P4HTM RSPH9 SAMD9 IGLL1 RPGR TNFRSF13B LTBP3 DNAL1 CFAP298 CYBA BTK MS4A1 ICOS DNAAF1 LIG4 CR2 ACADVL RAG1 GAS2L2 NSMCE3 CFAP221 SGCG FMO3 DNAAF6 DNAAF5 TTC25 PMM2 COL11A2 TCIRG1 TIMM8A SELENON RAG2 MUC5B SLC35A1 PGM3 EXTL3 KPTN CACNA1C CD3E CD19 CYBB LRRC6 KCNJ6 RNF168 IFNGR1 CD3D GAS8 CFTR PLOD1 POLA1 NBN PANK2 BLNK CFB WDR19 IL7R SP110 MCIDAS PTPRC TBCD CCDC40 NIPBL LEP NHLRC1 DDR2 DNAJB13 CCDC65 SNP 0
HP:0011947: Respiratory tract infection
Genes 645
CCDC103 GATA6 IL2RG COL13A1 NCF4 DNAI1 EPG5 CSPP1 RYR1 ABCA12 CACNA1B IL2RG POLR3A DNAAF2 TRAIP CLCA4 JAK3 SOX11 OFD1 IL17RC SLC12A6 IGHM TCTN3 NECTIN1 INSR IER3IP1 GAS8 DCLRE1C BCR NOTCH3 CLEC7A PSAP VPS33A LRRC56 PWRN1 ATM TGFB1 BCL10 RAG2 CCDC39 CD8A NKX2-1 OCRL DNAH11 CHD7 TINF2 FOXP3 RANBP2 CR2 RNU4ATAC SETBP1 CD3D MALT1 PLP1 HYDIN SPAG1 TAP2 AGA IRAK4 DNAH9 NELFA IL7R TNFSF12 RUNX2 DNAAF4 IL17RA ADA DNAI2 DNAH5 GRHL3 FOXP1 ATP6V0A2 DNAH1 LCK DNAI1 SMARCA4 ORC6 ELP1 MASP2 DCLRE1C SLC5A7 RSPH3 MTHFD1 NIPAL4 G6PC3 CCNO IRF8 CHAMP1 SLC52A3 CCDC39 PIK3CD SDCCAG8 NHP2 EPM2A SCNN1A MYSM1 CD81 TNFSF12 UNC119 CCDC65 ARMC4 RAG1 ARID2 LRBA NCF2 SMN1 CDCA7 FLNA DCLRE1C RMRP TBC1D23 TPM3 NFKB2 DSG1 NKX2-1 SFTPA2 SMPD1 UBE2A RAG2 FAT4 SNORD116-1 IPW MYO5A WAS CFTR KDM6A ICOS RYR1 SLC25A22 NFKB1 DNAH11 RPGR RAG1 SOX4 NCF1 ARSB NME8 ALMS1 ARMC4 DCLRE1C TSC1 STAT3 STAT3 CR2 TSC1 RAB3GAP2 GFI1 ARID1A TAF1 HACD1 ALB RNF125 ADAMTS3 UMPS LAMTOR2 LEPR SMARCB1 IDUA CARD11 LAMB2 CFTR CCDC151 USP9X LEP TECPR2 DNMT3B RSPH4A COL6A1 TNFSF11 BIRC3 RYR1 PRKDC GLB1 TYK2 PEPD HLA-DPA1 TCIRG1 LRRC56 CFTR FBLN5 SNORD115-1 TNFRSF13B SCNN1G GNPTAB CORO1A CXCR4 DNAAF6 IDUA SNX10 MED25 CFAP410 FCGR3A BTK GMNN ABCA12 RAC1 ACP5 EDARADD CD19 POLE GBA LAMA2 STAT1 LIPN NFKB2 DRC1 VPS13A WAS NFKB1 NFKB2 STK36 AK2 MGP GBA CCDC22 SLC1A4 RNF113A DNAJB13 SULT2B1 BLM TAP1 INPPL1 TNFRSF1A CFAP298 ZBTB24 PIK3R1 RPGR DNAH5 DNAL1 CFAP298 GATA2 BTK SMPD1 ICOS DCTN4 DKC1 FUCA1 DNAAF1 LIG4 CSF2RB ACADVL PRPS1 RAG1 GAS2L2 AGRN RIPK1 FMO3 SNAP25 CSF2RA PTPN22 INPPL1 ALPL MGP MAGEL2 HGSNAT DNAAF5 ELN TTC25 SLC25A1 DNAAF3 RAG2 TGFB1 FCN3 PMM2 RSPH9 CYBB SMARCE1 ASAH1 COL6A3 AICDA SLC35A1 ELANE IKBKB PGM3 CCDC40 CCDC103 ERCC2 KAT6B PEPD KRAS MCM4 CD3E COG4 SPINK5 CD19 SMARCC2 WASHC5 SLC18A3 WRAP53 KCNJ6 GLI3 STING1 MANBA DNAAF5 RFC2 MAPK1 ERCC3 CD3D WIPF1 MS4A1 TERC TGFB1 B2M POLA1 SHROOM4 NBN BLNK CYBC1 CFB IL7R SP110 MCIDAS MYL2 CTLA4 PRTN3 IL2RB CCDC40 EP300 IFIH1 ATM CHAT SCN10A KIF1A GNPTAB CRELD1 DNAJB13 TERT SCNN1B JAK3 ZMYND10 MKRN3-AS1 TPM2 CD247 DOCK8 MBTPS2 SCNN1A TRAF3IP2 PRKCD ACTA1 RSPH4A NGLY1 FLI1 COLQ LETM1 NFE2L2 CCNO RSPH1 TBCE VAMP1 TPP2 SAMD9L ZBTB24 ZAP70 CD3G NR2F2 OSTM1 LAMTOR2 TK2 GUSB CARMIL2 NRAS LRRC8A ARID1B CTCF SELENON LIMK1 GAA SLC46A1 CHRM3 TBL2 MYSM1 DNAI2 SLC29A3 RELB SDR9C7 CD3E NADK2 SPAG1 COL11A2 TNFRSF13C SFTPC RSPH3 SCNN1G IL2RG SH3KBP1 CD79B SRP54 EPG5 ICOS FCGR2A BACH2 UBB AFF4 MAP3K20 KIAA0586 IL7R HPS6 HERC2 TERT GSN RFX5 ERF IKBKB IL17RA SCNN1G LEPR CLCN7 SCN11A DPM2 NCF2 AFF4 EXOSC9 TRPS1 CCBE1 MYH3 ELANE NME8 COG6 CASP8 CARD11 DNAAF4 SLC35C1 DNAAF1 DPF2 KMT2D CD79A CLIP2 USB1 PYROXD1 LYST CCDC114 NBN BLNK TIRAP RFXAP PCGF2 TCF3 MECP2 CTSC TAPBP DNAAF2 NOTCH2 RSPH1 HLA-DPB1 GNS CD81 PGM3 SCNN1B ADA EGFR NCF4 GTF2E2 STAT1 PARN CCDC114 CFI RFXANK TNFRSF13C IL21R MSN TNFRSF13B RFXANK TBC1D24 SLC25A24 SGSH PTPN22 GATA4 PNP NFIX USB1 TSC2 CIITA IDUA GALNS RFXAP ADA DNMT3B RAG2 ITGA3 CFAP300 STX1A EHMT1 ITGA7 ADNP NGLY1 BTK MYO9A TTC25 SPEF2 IL2RG NCF1 ROR2 SCN9A SCNN1A TNFRSF13C MKRN3 NSD2 GTF2H5 ZNHIT3 TARS1 CXCR4 PIK3R1 RTEL1 TRIP11 CD55 OFD1 FOXJ1 HELLS ZMYND10 CYP4F22 NDN ALOXE3 COG4 NFKBIA AP3D1 CD79A PLEC SFTPC GAS2L2 MPLKIP RAG1 ALOX12B IGH RAG1 USP9X PIGN ALMS1 XIAP GBA NXN TFRC TSC2 ACTA1 PNP TNFRSF11A PCNT CD79B HLA-B GTF2I SH2D1A IL21 SMARCD2 ZAP70 RNU4ATAC DNAAF3 IL2RA P4HTM AGA ARID1B RSPH9 SAMD9 IGLL1 GUSB TNFRSF13B LTBP3 CYBA ASAH1 NPM1 IKZF1 CYBA KIAA0556 RFX5 MS4A1 ALG12 JAGN1 SLC26A2 CR2 NAGLU NSMCE3 PLG UNG CFAP221 SGCG COL13A1 DNAAF6 SIK1 LYST SNRPN TRIP4 PWAR1 ECM1 MESP2 TGM1 COL11A2 IRAK4 TCIRG1 TBC1D24 TIMM8A SELENON CD19 RAG2 IKBKG DLL3 MUC5B IL17F NPAP1 ELP1 BAZ1B HYDIN CTLA4 ZNF341 CIITA EXTL3 KPTN CACNA1C XIAP PEX13 PLCG2 COL6A2 CYBB PIK3R1 CTC1 LRRC6 NOP10 RNF168 IFNGR1 GAS8 CFTR PLOD1 SYT2 IGHM PANK2 WDR19 PTPRC MESP2 FOXP1 FLNA TBCD IGLL1 CRKL VPS33A SMN1 NIPBL LEP WDR34 SCNN1B NHLRC1 CCDC151 DOCK8 LRRC6 GTF2IRD1 CREBBP TBX6 DDR2 CCDC65 Protein Mutations 1
H275Y SNP 0
Primary Outcomes
Description: Number and severity of adverse events
Measure: Phase 1: Frequency and Severity of Adverse Events (AE) Time: Up to 12 monthsDescription: Time from the date of randomization to the clearance of SARS-CoV-2 by rRT-PCR
Measure: Time to Clearance of SARS-CoV-2 Time: Up to 12 monthsDescription: Time from the date of randomization to the first date of clinical improvement of cough.
Measure: Time to Clinical Improvement of cough Time: Up to 28 daysDescription: Time from the date of randomization to the first date of clinical improvement of radiological evaluation of disease related chest x-ray
Measure: Time to Clinical Improvement in radiological evaluation of disease related chest x-ray Time: Up to 28 daysDescription: Proportion of subjects who achieve pulmonary clearance
Measure: Rate of Pulmonary Clearance Time: Up to 28 daysDescription: Proportion of subjects who achieved clinical improvement of radiological evaluation of disease related chest x-ray
Measure: Rate of Clinical Improvement of radiological evaluation of disease related chest x-ray Time: Up to 28 daysSecondary Outcomes
Description: Number and severity of adverse events
Measure: Phase 2: Frequency and Severity of Adverse Events (AE) Time: up to 12 monthsDescription: Time to medical discharge as an assessment of overall clinical benefit
Measure: Overall Clinical Benefit by time to medical discharge Time: up to 12 monthsDescription: Hospital utilization will be measured as an assessment of overall clinical benefit
Measure: Overall Clinical Benefit by hospital utilization Time: up to 12 monthsDescription: Mortality rate will be measured as an assessment of overall clinical benefit
Measure: Overall Clinical Benefit by measuring mortality rate Time: up to 12 monthsDescription: Assess the impact of CYNK-001 on changes in sequential organ failure assessment (SOFA) score.
Measure: Impact of CYNK-001 on sequential organ failure assessment (SOFA) score Time: Up to 28 daysDescription: Time from randomization to the date of disappearance of virus from lower respiratory tract infection (LRTI) specimen where it has previously been found (induced sputum, endotracheal aspirate).
Measure: Time to Pulmonary Clearance Time: Up to 28 daysDescription: Proportion of subjects who achieved clinical improvement of cough
Measure: Rate of Clinical Improvement of cough Time: Up to 28 daysDescription: Proportion of subjects who achieved clinical improvement of fever
Measure: Rate of Clinical Improvement of fever Time: Up to 28 daysDescription: Time from the date of randomization to the first date of clinical improvement of fever
Measure: Time to Clinical Improvement of fever Time: Up to 28 daysDescription: Proportion of subjects with "negative" measurement of COVID-19 by rRT-PCR
Measure: Rate of Clearance of SARS-CoV-2 Time: Up to 12 months